RISANKIZUMAB-RZAA: 65,422 Adverse Event Reports & Safety Profile
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
65,422
Total FAERS Reports
2,269 (3.5%)
Deaths Reported
14,095
Hospitalizations
65,422
As Primary/Secondary Suspect
192
Life-Threatening
247
Disabilities
Prescription
Status
FDA Application: 761105 ·
First Report: 19890901 · Latest Report: 20250925
What Are the Most Common RISANKIZUMAB-RZAA Side Effects?
#1 Most Reported
Psoriasis
6,896 reports (10.5%)
#2 Most Reported
Drug ineffective
2,885 reports (4.4%)
#3 Most Reported
Pain
2,584 reports (3.9%)
All RISANKIZUMAB-RZAA Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Psoriasis | 6,896 | 10.5% | 12 | 778 |
| Drug ineffective | 2,885 | 4.4% | 6 | 379 |
| Pain | 2,584 | 4.0% | 18 | 571 |
| Fatigue | 2,483 | 3.8% | 4 | 446 |
| Arthralgia | 2,419 | 3.7% | 7 | 419 |
| Pruritus | 2,311 | 3.5% | 2 | 213 |
| Covid-19 | 2,145 | 3.3% | 55 | 640 |
| Death | 1,700 | 2.6% | 1,637 | 80 |
| Fall | 1,666 | 2.6% | 32 | 782 |
| Surgery | 1,662 | 2.5% | 5 | 245 |
| Headache | 1,554 | 2.4% | 5 | 239 |
| Diarrhoea | 1,427 | 2.2% | 7 | 475 |
| Crohn's disease | 1,338 | 2.1% | 12 | 685 |
| Device issue | 1,245 | 1.9% | 1 | 168 |
| Rash | 1,188 | 1.8% | 2 | 148 |
| Nasopharyngitis | 1,158 | 1.8% | 6 | 155 |
| Nausea | 1,104 | 1.7% | 10 | 370 |
| Therapeutic response shortened | 1,089 | 1.7% | 1 | 88 |
| Pneumonia | 1,079 | 1.7% | 55 | 744 |
| Erythema | 1,051 | 1.6% | 2 | 136 |
Who Reports RISANKIZUMAB-RZAA Side Effects? Age & Gender Data
Gender: 57.1% female, 42.9% male. Average age: 56.5 years. Most reports from: US. View detailed demographics →
Is RISANKIZUMAB-RZAA Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 0 | 0 |
| 2001 | 1 | 0 | 0 |
| 2002 | 1 | 0 | 0 |
| 2003 | 2 | 0 | 0 |
| 2004 | 3 | 0 | 0 |
| 2005 | 3 | 0 | 1 |
| 2006 | 2 | 0 | 1 |
| 2007 | 2 | 0 | 0 |
| 2008 | 6 | 0 | 6 |
| 2009 | 7 | 0 | 1 |
| 2010 | 6 | 0 | 1 |
| 2011 | 4 | 0 | 0 |
| 2012 | 10 | 0 | 0 |
| 2013 | 14 | 0 | 4 |
| 2014 | 18 | 0 | 4 |
| 2015 | 21 | 0 | 6 |
| 2016 | 19 | 0 | 5 |
| 2017 | 20 | 1 | 7 |
| 2018 | 56 | 0 | 10 |
| 2019 | 529 | 14 | 174 |
| 2020 | 1,721 | 92 | 676 |
| 2021 | 2,781 | 171 | 964 |
| 2022 | 9,160 | 185 | 1,174 |
| 2023 | 7,483 | 283 | 2,439 |
| 2024 | 9,058 | 333 | 3,009 |
| 2025 | 6,204 | 232 | 1,988 |
What Is RISANKIZUMAB-RZAA Used For?
| Indication | Reports |
|---|---|
| Psoriasis | 40,890 |
| Crohn's disease | 12,561 |
| Product used for unknown indication | 7,604 |
| Psoriatic arthropathy | 6,970 |
| Colitis ulcerative | 786 |
| Rheumatoid arthritis | 252 |
| Illness | 79 |
| Hidradenitis | 65 |
| Maternal exposure timing unspecified | 65 |
| Guttate psoriasis | 64 |
RISANKIZUMAB-RZAA vs Alternatives: Which Is Safer?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA
RISANKIZUMAB-RZAA vs RISPERIDONE
RISANKIZUMAB-RZAA vs RITALIN
RISANKIZUMAB-RZAA vs RITLECITINIB
RISANKIZUMAB-RZAA vs RITODRINE
RISANKIZUMAB-RZAA vs RITONAVIR
Official FDA Label for RISANKIZUMAB-RZAA
Official prescribing information from the FDA-approved drug label.